Return to Diabetes Alert Section
Investigators at University of Maryland zero in on type 2 diabetes
November 19th, 2007
2007 NOV 19 -- "The sulfonylurea receptor 1-regulated NCCa-ATP channel is upregulated in rodent models of stroke with block of the channel by the sulfonylurea, glibenclamide (glyburide), significantly reducing mortality, cerebral edema, and infarct volume. We hypothesized that patients with type 2 diabetes mellitus taking sulfonylurea agents both at the time of stroke and during hospitalization would have superior outcomesWe reviewed medical records of patients with diabetes mellitus hospitalized within 24 hours of onset of acute ischemic stroke in the Neurology Clinic, Charite Hospital, Berlin, Germany, during 1994 to 2000," researchers in the United States report. "After exclusions, the cohort comprised 33 patients taking a sulfonylurea at admission through discharge (treatment group) and 28 patients not on a sulfonylurea (control group). The primary outcome was a decrease in National Institutes of Health Stroke Scale of 4 points or more from admission to discharge or a discharge National Institutes of Health Stroke Scale score of 0. The secondary outcome was a discharge modified Rankin Scale score <= 2No significant differences, other than stroke subtype, were observed among baseline variables between control and treatment groups. The primary outcome was reached by 36.4% of patients in the treatment group and 7.1% in the control group (P = 0.007). The secondary outcome was reached by 81.8% versus 57.1% (P = 0.035). Subgroup analyses showed that improvements occurred only in patients with nonlacunar strokes and were independent of gender, previous transient ischemic attack, and blood glucose levelsSulfonylureas may be beneficial for patients with diabetes mellitus with acute ischemic stroke," wrote H. Kunte and colleagues, University of Maryland. The researchers concluded: "Further investigation of similar cohorts and a prospective randomized trial are recommended to confirm the present observations." Kunte and colleagues published their study in Stroke (Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke, 2007;38(9):2526-2530). For additional information, contact J.M. Simard, University of Maryland, Dept. of Neurosurgery, 22 S Greene St., Suite 12SD, Baltimore, MD 21201, USA. Publisher contact information for the journal Stroke is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA. Keywords: United States, Baltimore, Non-insulin Dependent Diabetes Mellitus, Type 2 Diabetes Mellitus, University of Maryland. This article was prepared by Diabetes Week editors from staff and other reports. Copyright 2007, Diabetes Week via NewsRx.com.
Return to Diabetes Alert Section
|
